
RARX
Healthcare · Biotechnology · $2.27B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2020
EPS trend, 90 days to now · -3.2% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 7, 2019 | Time not confirmed | -0.52 | -0.47 | +8.9% |
| Nov 8, 2018 | Time not confirmed | -0.49 | -0.51 | -4.1% |
| Aug 8, 2018 | Time not confirmed | -0.55 | -0.49 | +11.4% |
| May 10, 2018 | Time not confirmed | -0.56 | -0.61 | -8.1% |
| Mar 15, 2018 | Time not confirmed | -0.66 | -0.67 | -1.4% |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead…